Cargando…
Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
Immune checkpoint modulation has been a vital therapeutic option in many malignancies, and targeting of novel immune checkpoints, including OX40/OX40L costimulatory signaling, is being assessed in clinical trials. However, little is known about the role of OX40 and OX40L in pancreatic ductal adenoca...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352865/ https://www.ncbi.nlm.nih.gov/pubmed/35936015 http://dx.doi.org/10.3389/fimmu.2022.942154 |
_version_ | 1784762741962047488 |
---|---|
author | Chen, Xianlong Ma, Heng Mo, Shengwei Zhang, Yue Lu, Zhaohui Yu, Shuangni Chen, Jie |
author_facet | Chen, Xianlong Ma, Heng Mo, Shengwei Zhang, Yue Lu, Zhaohui Yu, Shuangni Chen, Jie |
author_sort | Chen, Xianlong |
collection | PubMed |
description | Immune checkpoint modulation has been a vital therapeutic option in many malignancies, and targeting of novel immune checkpoints, including OX40/OX40L costimulatory signaling, is being assessed in clinical trials. However, little is known about the role of OX40 and OX40L in pancreatic ductal adenocarcinoma (PDAC). Thus, we investigated the clinical significance of OX-40 and OX40L and their associations with alternative immune checkpoints, immune infiltrates, clinicopathological features, and clinical outcomes. We performed multiplexed immunofluorescence staining for OX40, OX40L, CD8, and CD68 using tissue microarrays from 255 patients. Immunohistochemistry data for PD-L1, B7-H3, B7-H4, CD3, and Foxp3 were analyzed. And the RNA sequencing data of OX40/OX40L in The Cancer Genome Atlas and International Cancer Genome Consortium databases were also evaluated. The positive rates for OX40 on tumor cells (TCs) and immune cells (ICs) were 8.6% and 10.2%, respectively, and the positive rates for OX40L on TCs, ICs, and macrophages were 20%, 40.4%, and 12.9%, respectively. OX40 was associated with favorable clinicopathological features. OX40+ on ICs, OX40L+ on TCs, or OX40L+ on macrophages, rather than the total gene and protein levels of OX40/OX40L, were associated with improved survival. OX40+ on ICs and OX40L+ on macrophages were independent factors of clinical outcomes. Moreover, we could more accurately stratify patients through the combination of OX40 on ICs and OX40L on TCs, and patients with OX40+ ICs and OX40L+CK+ showed the best outcome. And we demonstrated that patients with OX40-ICs and low CD8+ T cells infiltration had unfavorable survival. Intriguingly, OX40+ ICs or OX40L+ macrophages demonstrated superior survival in patients with PD-L1 negativity than in those with PD-L1 positivity. Furthermore, OX40+ ICs were correlated with negative B7-H4 on TCs, high densities of CD3 T cells, and high densities of Foxp3 T cells; OX40+ TCs and OX40L+ TCs were associated with low densities of Foxp3 T cells. We identified OX40 and OX40L as promising predictors for prognosis in PDAC. |
format | Online Article Text |
id | pubmed-9352865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93528652022-08-06 Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma Chen, Xianlong Ma, Heng Mo, Shengwei Zhang, Yue Lu, Zhaohui Yu, Shuangni Chen, Jie Front Immunol Immunology Immune checkpoint modulation has been a vital therapeutic option in many malignancies, and targeting of novel immune checkpoints, including OX40/OX40L costimulatory signaling, is being assessed in clinical trials. However, little is known about the role of OX40 and OX40L in pancreatic ductal adenocarcinoma (PDAC). Thus, we investigated the clinical significance of OX-40 and OX40L and their associations with alternative immune checkpoints, immune infiltrates, clinicopathological features, and clinical outcomes. We performed multiplexed immunofluorescence staining for OX40, OX40L, CD8, and CD68 using tissue microarrays from 255 patients. Immunohistochemistry data for PD-L1, B7-H3, B7-H4, CD3, and Foxp3 were analyzed. And the RNA sequencing data of OX40/OX40L in The Cancer Genome Atlas and International Cancer Genome Consortium databases were also evaluated. The positive rates for OX40 on tumor cells (TCs) and immune cells (ICs) were 8.6% and 10.2%, respectively, and the positive rates for OX40L on TCs, ICs, and macrophages were 20%, 40.4%, and 12.9%, respectively. OX40 was associated with favorable clinicopathological features. OX40+ on ICs, OX40L+ on TCs, or OX40L+ on macrophages, rather than the total gene and protein levels of OX40/OX40L, were associated with improved survival. OX40+ on ICs and OX40L+ on macrophages were independent factors of clinical outcomes. Moreover, we could more accurately stratify patients through the combination of OX40 on ICs and OX40L on TCs, and patients with OX40+ ICs and OX40L+CK+ showed the best outcome. And we demonstrated that patients with OX40-ICs and low CD8+ T cells infiltration had unfavorable survival. Intriguingly, OX40+ ICs or OX40L+ macrophages demonstrated superior survival in patients with PD-L1 negativity than in those with PD-L1 positivity. Furthermore, OX40+ ICs were correlated with negative B7-H4 on TCs, high densities of CD3 T cells, and high densities of Foxp3 T cells; OX40+ TCs and OX40L+ TCs were associated with low densities of Foxp3 T cells. We identified OX40 and OX40L as promising predictors for prognosis in PDAC. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9352865/ /pubmed/35936015 http://dx.doi.org/10.3389/fimmu.2022.942154 Text en Copyright © 2022 Chen, Ma, Mo, Zhang, Lu, Yu and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Chen, Xianlong Ma, Heng Mo, Shengwei Zhang, Yue Lu, Zhaohui Yu, Shuangni Chen, Jie Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma |
title | Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma |
title_full | Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma |
title_fullStr | Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma |
title_full_unstemmed | Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma |
title_short | Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma |
title_sort | analysis of the ox40/ox40l immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352865/ https://www.ncbi.nlm.nih.gov/pubmed/35936015 http://dx.doi.org/10.3389/fimmu.2022.942154 |
work_keys_str_mv | AT chenxianlong analysisoftheox40ox40limmunoregulatoryaxiscombinedwithalternativeimmunecheckpointmoleculesinpancreaticductaladenocarcinoma AT maheng analysisoftheox40ox40limmunoregulatoryaxiscombinedwithalternativeimmunecheckpointmoleculesinpancreaticductaladenocarcinoma AT moshengwei analysisoftheox40ox40limmunoregulatoryaxiscombinedwithalternativeimmunecheckpointmoleculesinpancreaticductaladenocarcinoma AT zhangyue analysisoftheox40ox40limmunoregulatoryaxiscombinedwithalternativeimmunecheckpointmoleculesinpancreaticductaladenocarcinoma AT luzhaohui analysisoftheox40ox40limmunoregulatoryaxiscombinedwithalternativeimmunecheckpointmoleculesinpancreaticductaladenocarcinoma AT yushuangni analysisoftheox40ox40limmunoregulatoryaxiscombinedwithalternativeimmunecheckpointmoleculesinpancreaticductaladenocarcinoma AT chenjie analysisoftheox40ox40limmunoregulatoryaxiscombinedwithalternativeimmunecheckpointmoleculesinpancreaticductaladenocarcinoma |